Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Q4 FY2012-13 Earnings Presentation
46 slides from Alembic Pharmaceuticals's earnings presentation, March 2013
Slide 1: Investor Presentation
Alembic Pharmaceuticals Limited Investor Presentation March 2013 BSE: Symbol: ALEMPHARM Code: 533573 NSE: Symbol: APLLTD ISIN: INE901L01018 www.alembic-india.com
Slide 2: Safe Harbour Statement
Safe Harbour Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diff
Slide 3: Agenda
Agenda The Alembic Journey Insight - Alembic Overview Insight - Strategic Advantage Growth Drivers Business Strategy and Approach Financials Corporate Social Responsibility
Slide 4: Agenda
Agenda The Alembic Journey Insight - Alembic Overview Insight - Strategic Advantage Growth Drivers Business Strategy and Approach Financials Corporate Social Responsibility
Slide 5: The Alembic Journey
The Alembic Journey 2003 State-of-the-art 2001 Formulations facility for Starts Regulatory 1972 manufacturing of Markets "Althrocin"- a Cephalosporin C 1971 brand of Erythromycin Erythromycin launched 1961 manufactured for the first Lal Bahadur time in India 1940 Shastri, the then Started Prime mini
Slide 6: The Alembic Journey
The Alembic Journey 2012 - Para IV filed 2011 - Cumulatively - ANVISA 57 ANDAs filed, (24 ANDA approved) 2010 approvals - Aggressive and 60 DMFs - Azithral sales ANDAs and 2009 Reach INR 1000 million DMFs filing Addressed mark 2007 chronic therapies - Demerger AL-APL through Acquisition of multiple
Slide 7: Agenda
Agenda The Alembic Journey Insight - Alembic Overview Insight - Strategic Advantage Growth Drivers Business Strategy and Approach Financials Corporate Social Responsibility
Slide 8: Insight - Alembic Overview
Insight - Alembic Overview Branded Formulations Revenue of INR 8860 million Ranked 22nd in the Ranked 15th in Well equipped in the domestic market for Indian Formulations Doctors Prescription Formulations Plant the financial year 2012-13 market with a market Universe** located at Baddi, share of 1.7
Slide 9: Insight - Alembic Overview
Insight - Alembic Overview International Division Business size of Sales in Regulatory 1 US FDA World-class INR 5960 million in the Generics Market of INR 2450 approved R&D and F&D financial year 2012-13 million in the financial year Formulations facility 2012-13 Plant Alliances with leading Robust
Slide 10: Business Portfolio
Business Portfolio R&D BRANDED Alliances API Quality FORMULATIONS Business Synergies INTERNATIONAL Manufacturing GENERICS Efficiency
Slide 11: Agenda
Agenda The Alembic Journey Insight - Alembic Overview Insight - Strategic Advantage Growth Drivers Business Strategy and Approach Financials Corporate Social Responsibility
Slide 12: Strategic Advantage
Strategic Advantage Alembic Research Centre is Well-developed the first in India to be Infrastructure facility - Information Security Certified 4 US FDA approved plants Highly talented pool of High-end quality / 300 Research Scientists RA structure R&D / F&D / Captive Manufacturing excellence Bio-eq
Slide 13: Manufacturing Infrastructure
Manufacturing Infrastructure Formulations - Generics Branded Formulations API (Regulatory Markets) USFDA, MCC, MHRA, Formulations plant at USFDA, EDQM, TGA, WHO ANVISA, TPD approved Baddi, Himachal Pradesh approved API facility at formulations facility at Panelav Panelav (2 units) and at Karkhadi (1
Slide 14: Manufacturing Infrastructure - Certifications
Manufacturing Infrastructure Certifications
Slide 15: Alembic Research Centre
Alembic Research Centre State-of-the-art Analytical & IPR infrastructure R&D FACILITY F&D CAPABILITIES BIO EQUIVALENCE CENTRE R&D Centre has been Expertise in Drug Deliveries State-of-the-art 90-bedded new recognized by DSIR, and Niche Formulations Bio Centre Govt. of India Well-defined Processes Hi
Slide 16: Research Capabilities
Research Capabilities 57 ANDA Filing ANDAs filed 60 with DMFs Filing DMFs filed 24 ANDA / NDA 60 57 54 approvals 44 45 37 32 26 25 18 18 11 18 13 13 12 11 9 8 7 7 7 6 6 Up to 2008-09 2009-10 2010-11 2011-12 2012-13 Up to 2008-09 2009-10 2010-11 2011-12 2012-13 2007-08 2007-08
Slide 17: Global Presence
Global Presence 23 ANDA Approvals: Pramipexole Dihydrochloride Tablets Lamotrigine Tablets Famotidine Tablets USP Losartan Potassium Tablets (Para IV) Venlafaxine Hydrochloride Tablets Irbesartan Tablets USP (Para IV) Lithium Carbonate Capsules USP Hydrochlorothiazide Capsules USA / Metronidazole Ta
Slide 18: Effective Marketing
Effective Marketing PAN India Marketing and Distribution Network OSTEOFIT ZENOVI Orthopedics Gynecology SPECIA Cardiology Diabetes SUMMIT Urology Cardiology INTENSA ENTERON EYECARE Diabetes Critical Care Gastrology Ophthalmology ALCARE MAXIS OTC & Rural General Focused SPECIALITY PHARMA MEGACARE Gen
Slide 19: Effective Marketing
Effective Marketing PAN India Marketing and Distribution Network GENERICS & NSA VETERINARY OTHER PRODUCT PORTFOLIO
Slide 20: Major Product Portfolio
Major Product Portfolio Top Therapatic Ranking* Other Therapatic Products Area Products Area Azithral Anti Infective 26 Ulgel Antacid and Anti Flatulant Zeet/Bro-Zeet Cough & Cold Althrocin Anti Infective 50 Tellzy Cardiology Roxid Anti Infective 145 Gestofit Gynecology Sharkoferrol Tonic Wikoryl Co
Slide 21: Agenda
Agenda The Alembic Journey Insight - Alembic Overview Insight - Strategic Advantage Growth Drivers Business Strategy and Approach Financials Corporate Social Responsibility
Slide 22: Growth Drivers
Growth Drivers Branded Formulation Business International Generic Business CAGR INR million CAGR INR million 9 13% % 37 55%% 8860 2450 2550 7830 6930 1020 2010-11 2011-12 2012-13 2010-11 2011-12 2012-13
Slide 23: Growth Drivers - Branded Formulations
Growth Drivers Branded Formulations Enhanced focus on existing branded business Expected Through effective pan-India distribution annual growth network and therapy based marketing and by pushing ahead acute and chronic 15-18% segments like anti-infectives and cough & cold medications Launch 20-25 ne
Slide 24: Growth Drivers - Domestic Market
Growth Drivers Domestic Market Continued capitalization of Dabur Pharma’s assets Expected The non-oncology business of Dabur annual growth Pharma was acquired in 2007. Further capitalization of its assets will yield a 15-18% stronger product line. Enter into new therapeutic segment Future indentifie
Slide 25: Growth Drivers - International Generics
Growth Drivers International Generics Superior cost efficiency Expected CAGR of Position Alembic as a cost efficient dependable quality manufacturer 30% Expanded annual production capacity Annual production to increase from 2.6 billion tablets/capsules to 5 billion tablets/capsules in 2013-14
Slide 26: Growth Drivers - International Generic Formulation
Growth Drivers International Generic Formulation ANDA filings and approvals for off-patent drugs Expected CAGR of Over the next five years, products that currently generate more than USD 142 billion 30% In sales are expected to go off-patent. Alembic can tap these opportunities by launching new gene
Slide 27: Agenda
Agenda The Alembic Journey Insight - Alembic Overview Insight - Strategic Advantage Growth Drivers Business Strategy and Approach Financials Corporate Social Responsibility
Slide 28: Business Strategy & Approach
Business Strategy & Approach Sustainable Vertical High Growth in Business Streams Integration Advanced Markets Retaining and consolidating Vertical integration in R&D Partner in international strong presence in acute and manufacturing of market through alliances therapies in the domestic intermediat
Slide 29: Agenda
Agenda The Alembic Journey Insight - Alembic Overview Insight - Strategic Advantage Growth Drivers Business Strategy and Approach Financials Corporate Social Responsibility
Slide 30: Financial Highlights – Quarterly
Financial Highlights – Quarterly Consolidated Q IV - FY 12-13 INR million Sales Q IV / 12-13 Q IV / 11-12 Business Share '12 Growth % Formulation Branded Domestic 1,796 1,572 47% 14% Generic & NSA 279 273 7% 2% Branded International 128 177 3% (28)% Total 2,203 2,022 57% 9% International Division In
Slide 31: Financial Highlights – Quarterly
Financial Highlights – Quarterly Result Highlight (Consolidated) Q IV - FY 12-13 INR million Particulars Q IV / 12-13 Q IV / 11-12 Growth % EBDITA 877 634 38% (Before R&D) R&D Expenses 220 221 - EBDITA 657 413 59% (Post R&D) PBT 552 269 105% PAT 437 203 115%
Slide 32: Financial Highlights – 2012-13
Financial Highlights – 2012-13 Consolidated 2012-13 INR million Sales 2012-13 2011-12 Business Share '12 Growth % Formulation Branded Domestic 7,696 6,750 50% 14% Generic & NSA 1,167 1,076 8% 8% Branded International 441 567 3% (22)% Total 9,304 8,393 61% 11% International Division International Gen
Slide 33: Financial Highlights – 2012-13
Financial Highlights – 2012-13 Result Highlight (Consolidated) 2012-13 INR million Particulars 2012-13 2011-12 Growth % EBDITA 3295 2795 18% (Before R&D) R&D Expenses 736 586 - EBDITA 2559 2209 16% (Post R&D) PBT 2064 1610 28% PAT 1,653 1301 27%
Slide 34: Revenue Overview
Revenue Overview Sales Composition Q IV – FY 12-13 API Export Export Incentive 14% 1% API Domestic 7% Domestic Branded Formulations International Generics 47% 21% International Branded Formulations Generic & NSA 3% 7%
Slide 35: Revenue Overview
Revenue Overview Sales Composition Q IV – FY 12-13 Therapy Based Sales Break up Business Anti Infectives 36% Gastrology 17% Domestic Cough & Cold 13% Branded Business Cardiology 11% Gynecology 10% Orthopedics 5% Anti Diabetic 4% Nephrology/Urology 3% Ophthalmology 1%
Slide 36: Revenue Overview
Revenue Overview Sales Composition Q IV – FY 12-13 Business Global Sales break up Europe 29% International Generics International Generics USA / Canada 71%
Slide 37: Revenue Overview
Revenue Overview Sales Composition 2012 - 2013 API Export Export Incentive 16% 1% API Domestic 7% Domestic Branded Formulations 50% International Generics 15% International Branded Formulations 3% Generic & NSA 8%
Slide 38: Revenue Overview
Revenue Overview Sales Composition 2012- 2013 Business Global Sales break up Europe 35% International Generics USA / Canada 65%
Slide 39: R & D Expense
R & D Expense Increased Thrust on Research to create Intellectual Property R&D spend as a % to Sales 5.06% 4.78% 4.30% 4.06% 3.60% 2008-09 2009-10 2010-11 2011-12 2012-13
Slide 40: Financial Snapshot
Financial Snapshot SALES PBIDTA CAGR CAGR 713% % INR million 26 % 21 INR million 15260 2559 14679 2209 12066 1603 2010-11 2011-12 2012-13 2010-11 2011-12 2012-13
Slide 41: Shareholding Pattern
Shareholding Pattern Alembic Pharmaceuticals Limited Promoters & Promoter Group 45% Alembic Limited Public 29% 18% FI / FII / MF Total Paid up Capital 8% INR 377.03 million 188.52 million Total No. of Shareholders 46,350 As on 31st March 2013
Slide 42: Agenda
Agenda The Alembic Journey Insight - Alembic Overview Insight - Strategic Advantage Growth Drivers Business Strategy and Approach Financials Corporate Social Responsibility
Slide 43: Corporate Social Responsibility
Corporate Social Responsibility Rural Development Society Rural Development Society is a Social Responsibility Initiative of Alembic founded in 1979 Enhancement for self employment and income generation for economic development School, hostel and medical facilities for local villagers
Slide 44: Corporate Social Responsibility
Corporate Social Responsibility Environment Alembic believes in clean and green chemistry Zero discharge facilities comprising of state-of-the-art aeration system, ultra filtration and reverse osmosis plant, evaporation and incineration plant Dedicated scrubbing system for process gas emissions
Slide 45: Alembic Pharmaceuticals Limited
For updates and specific queries, please visit: www.alembic-india.com or feel free to contact Mitanshu Shah Tel.: 0265 - 300 7630 • Fax: 0265 - 228 2506 mitanshu.shah@alembic.co.in Alembic Pharmaceuticals Limited Alembic Road, Vadodara 390 003, India .Tel.: 0265 – 300 7000
Slide 46: Thank You
An, Touching Lives over 10> Thank You
Alembic Pharmaceuticals — Q4 FY2012-13 Earnings Presentation on 6ix